Combined treatment of tyrosine kinase inhibitor labeled gold nanorod encapsulated albumin with laser thermal ablation in a renal cell carcinoma model

Authors: CALLAGHAN, CAMERON - Tulane School Of Medicine; Peralta, Donna; LIU, JAMES - Tulane School Of Medicine; MANDAVA, SREE HARSHA - Tulane School Of Medicine; MADDOX, MICHAEL - Tulane School Of Medicine; DASH, SRIKANTA - Tulane School Of Medicine; TARR, MATTHEW - University Of New Orleans; LEE, BENJAMIN - Tulane School Of Medicine

Submitted to: Journal of Pharmaceutical Sciences
Publication Type: Peer Reviewed Journal
Publication Acceptance Date: 11/6/2015
Publication Date: 1/13/2016
Citation: Callaghan, C., Peralta, D.V., Liu, J., Mandava, S.H., Maddox, M., Dash, S., Tarr, M.A., Lee, B.R. 2016. Combined treatment of tyrosine kinase inhibitor labeled gold nanorod encapsulated albumin with laser thermal ablation in a renal cell carcinoma model. Journal of Pharmaceutical Sciences. 105(1):284-292. https://doi.org/10.1016/j.xphs.2015.11.017.
DOI: https://doi.org/10.1016/j.xphs.2015.11.017

Interpretive Summary: This manuscript served to characterize and evaluate Human Serum Albumin-encapsulated Nanoparticles (NPs) for drug delivery of a tyrosine kinase inhibitor combined with induction of photothermal ablation (PTA) combination therapy of Renal Cell Carcinoma (RCC). RCC is the most common type of kidney cancer; usually affecting those between the ages of 50-70 years of age. Protein wrapped gold nanorods serve as a method to introduce chemotherapeutic drugs and induce heating by utilizing a near-IR laser. NPs of varying preparations and concentrations were characterized and cytotoxicity and uptake trials were also studied. Target temperatures of >50°C were consistently attained by 0.1 and 0.05 'M concentrations of irradiated HSAP-AuNRs. Photothermal ablation using HSAP-AuNRs is capable of inducing significant hyperthermia while the loading of Sorafenib further enhances cytotoxicity relative to treatment with HSAP-AuNRs alone. HSAP-AuNR-Sors have the potential to be an effective, novel combination treatment for advanced RCC.

Technical Abstract: This manuscript served to characterize and evaluate Human Serum Albumin-encapsulated Nanoparticles (NPs) for drug delivery of a tyrosine kinase inhibitor combined with induction of photothermal ablation (PTA) combination therapy of Renal Cell Carcinoma (RCC). RCC is the most common type of kidney cancer; usually affecting those between the ages of 50-70 years of age. Protein wrapped gold nanorods serve as a method to introduce chemotherapeutic drugs and induce heating by utilizing a near-IR laser. NPs of varying preparations and concentrations were characterized and cytotoxicity and uptake trials were also studied. Target temperatures of >50°C were consistently attained by 0.1 and 0.05 'M concentrations of irradiated HSAP-AuNRs. Photothermal ablation using HSAP-AuNRs is capable of inducing significant hyperthermia while the loading of Sorafenib further enhances cytotoxicity relative to treatment with HSAP-AuNRs alone. HSAP-AuNR-Sors have the potential to be an effective, novel combination treatment for advanced RCC.